Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Accumulated Expenses: 2015-2024

Historic Accumulated Expenses for Cartesian Therapeutics (RNAC) over the last 10 years, with Dec 2024 value amounting to $12.1 million.

  • Cartesian Therapeutics' Accumulated Expenses fell 18.51% to $7.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.7 million, marking a year-over-year decrease of 18.51%. This contributed to the annual value of $12.1 million for FY2024, which is 22.45% down from last year.
  • Cartesian Therapeutics' Accumulated Expenses amounted to $12.1 million in FY2024, which was down 22.45% from $15.6 million recorded in FY2023.
  • In the past 5 years, Cartesian Therapeutics' Accumulated Expenses ranged from a high of $15.6 million in FY2023 and a low of $8.1 million during FY2020.
  • Moreover, its 3-year median value for Accumulated Expenses was $14.1 million (2022), whereas its average is $13.9 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first slumped by 39.62% in 2020, then surged by 33.71% in 2022.
  • Over the past 5 years, Cartesian Therapeutics' Accumulated Expenses (Yearly) stood at $8.1 million in 2020, then rose by 29.30% to $10.5 million in 2021, then soared by 33.71% to $14.1 million in 2022, then grew by 10.57% to $15.6 million in 2023, then decreased by 22.45% to $12.1 million in 2024.